Clinical Outcomes and Healthcare Resource Utilization in a Real-World Population Reflecting the DAPA-CKD Trial Participants
ConclusionThe significant adverse renal and cardiovascular outcomes observed, particularly in the DAPA-CKD-like cohort, represent a substantial burden resulting in increased mortality, HCRU and costs, demonstrating the need for additional treatment options.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Dapagliflozin | Diabetes | Diabetes Type 2 | Dialysis | Drugs & Pharmacology | Endocrinology | Forxiga | Healthcare Costs | Heart | Heart Attack | Heart Failure | Heart Transplant | Kidney Transplant | Kidney Transplantation | Stroke | Transplant Surgery | Transplants | Urology & Nephrology